Citations

Clear

15 citation(s) found for "Patel, Parth".

Risk-adapted step-up local therapy for malignant portal vein tumor thrombus from hepatic metastases: A real-world study of microwave ablation with and without iodine-125 seed implantation.
Pham, Hoang Tran , Chun, Li, Bao, Weidong, Tian, Shichao, Zhao, Qingsong, Zhang, Mingyi , Yang, Z Y, Alba, Margarita De, Dong, Zhongyi , Parker, Jefferson , Morecroft, Renee, Elalfy, Aya, COTTLE, CHASEN, Ingram, Demarcus, Abdel-Hakeem, Ahmed, Bains, Shifali, Patel, Parth, Ali, Muhammad, Yang, Vivienne , Pham, Hoang Tran, Morecroft, Renée , Elalfy, Aya, Patel, Parth, Hartzell, Shannon

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4235-4235

10.1200/jco.2026.44.16_suppl.4235 Get It

4235 Background: Malignant portal vein tumor thrombus (PVTT) arising from hepatic metastases is associated with poor prognosis, rapid hepatic decompensation, and limited effective local treatment options despite systemic therapy. In real-world practice, local treatment intensity is frequently adapted to disease burden and treatment response. We evaluated outcomes of a risk-adapted, step-up local treatment strategy using microwave ablation (MWA) alone or in combination with iodine-125 (I-125) seed implantation for patients with malignant PVTT. Methods: We retrospectively reviewed patients with hepatic metastases treated with MWA with or without I-125 seed implantation between 2023 and July 2025. In clinical practice, MWA alone was preferentially used for patients with relatively limited disease burden, while MWA plus I-125 was employed as an escalation strategy for patients with more advanced PVTT or disease progression following MWA alone. The primary endpoint was PVTT-directed local outcome, defined as portal vein patency and/or local control of tumor thrombus on follow-up imaging. Secondary endpoints included progression-free survival (PFS), overall survival (OS), hepatic function changes, and treatment-related toxicity. Survival analyses were considered exploratory. Results: A total of 73 patients were included, of whom 50 were treated with MWA alone and 23 with MWA plus I-125 seed implantation. Patients receiving MWA plus I-125 demonstrated more advanced disease characteristics, including universal presence of PVTT and higher disease stage, consistent with treatment escalation by disease severity. Among patients with PVTT, MWA plus I-125 achieved portal vein patency and/or local control in 65% at first follow-up imaging. Treatment-related toxicities were manageable, with no unexpected grade ≥3 adverse events attributable to I-125 implantation. Median PFS was 11.5 months in patients treated with MWA alone and 9.9 months in patients treated with MWA plus I-125, consistent with greater baseline disease burden in the latter group. Conclusions: MWA alone and MWA plus I-125 function as complementary components of a risk-adapted, step-up local treatment strategy for malignant PVTT from hepatic metastases. Escalation to MWA plus I-125 appears feasible in patients with advanced or refractory PVTT and demonstrates a potential signal for improved PVTT-directed local control and portal vein patency. Prospective studies focused on PVTT-specific endpoints are warranted.
Efficacy of CD38 ‐Targeted Therapy in Severe, Multi‐Agent Refractory Immune Thrombocytopenia: A Case Series
Patel, Parth , Farrugia, Stefan L. , Nunnelee, Jordan , Mina, Syeda, Go, Ronald S. , Rajkumar, S. Vincent, Rajkumar, S. Vincent , Patel, Parth S , Farrugia, Stefan, Go, Ronald S , Rajkumar, S Vincent , Mina, Syeda A. , Godby, Richard

Mayo Clinic

European Journal of Haematology | April 2, 2026 | Volume: 117 | Issue: 1 | Pages: 279-282

10.1111/ejh.70180 | PMID 41923527 Get It

ABSTRACT Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by antibody‐mediated platelet destruction, often driven by long‐lived plasma cells (LLPCs) resistant to conventional therapies. While most patients respond to corticosteroids and intravenous immunoglobulin (IVIG), a subset develops life‐threatening refractory disease. In this case series, we describe three patients aged 39, 85, and 58 with life‐threatening, multi‐agent refractory ITP and platelet nadirs < 2 × 10 9 /L who failed corticosteroids, IVIG, and thrombopoietin receptor agonists (TPO‐RAs). Following salvage therapy with daratumumab, a monoclonal antibody targeting CD38, all three patients achieved rapid hematologic recovery, with platelet count normalization within 1 week. This accelerated response allowed for urgent clinical stabilization, including safe anticoagulation and surgical intervention. The efficacy of daratumumab likely stems from a dual mechanism: the depletion of CD38+ LLPCs and the immediate modulation of Fc‐receptor‐mediated platelet clearance. These observations suggest that CD38‐targeted therapy can bypass traditional treatment resistance to achieve near‐immediate remission in high‐complexity, high‐risk clinical settings. While these results are compelling, prospective clinical trials are warranted to define the long‐term safety, durability, and optimal dosing of anti‐CD38 therapies in refractory ITP populations.
What is the ideal orthopaedic call plan for a level one trauma center?
Patel, Parth, Brutus, Katja, Crain, Andrew , Dahiya, Rockey , Foster, Cameron, Madbak, Firas , Young, Porter

Mayo Clinic

Orthopedic Reviews | December 22, 2025 | Volume: 17 | Issue: No issue available | Pages: No page available

10.52965/001c.154365 | PMID 41450482 Get It

Background Level I trauma centers employ various orthopaedic call strategies based on resources and surgeon subspeciality availability. Objective We hypothesize when surgeons fellowship trained in trauma are solely on call that patient outcomes will be improved compared to a combined plan. Methods Retrospective cohort study from two 24-month time periods at an academic level one trauma center. The first cohort consisted of only trauma surgeons taking call. The second cohort consisted of a combination of trauma and other subspecialities taking call. The primary outcome analyzed was time from admission to operating room for hip, femoral shaft, distal femur, tibia shaft, pelvic ring and acetabulum fractures. Secondary outcomes analyzed included length of stay, 90 day incidence of reoperation, mortality, VTE and readmission. Results Eight hundred and fifty seven patients in the trauma cohort and 992 patients in the combined cohort met the inclusion criteria. The time from admission to index surgical procedure was significantly shorter in the trauma cohort (1.7 vs 2.4). Length of stay (8.95 vs 11 days) and 90 day mortality (1.8% vs 3.8%) was improved in the trauma cohort. There was no difference in 90 day rate of VTE, readmission or reoperation. Length of stay and time to OR in pelvic ring injuries and acetabulum fractures were doubled compared to the hybrid group. Conclusions Our findings suggest that when trauma fellowship trained surgeons are the only ones taking call patients have a shorter time from admission to index surgical procedure, length of stay and lower mortality rate.
Abstract 4341751: Outcomes Associated with Infective Endocarditis in Cardiac Intensive Care Unit Patients
Patel, Parth , Kashou, Anthony H. , Murphy, Joseph G. , Sehrawat, Ojasav , Hashem, Anas , Noseworthy, Peter A. , Crestanello, Juan A. , Jentzer, Jacob C.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4341751 Get It

Introduction: Infective endocarditis (IE) is a severe intracardiac infection, often requiring intensive care unit (ICU) admission. Despite early surgical intervention, mortality remains high. Data for patients admitted to the cardiac intensive care unit (CICU) is especially limited. Research Question: We aimed to investigate the short and long-term outcomes of patients with IE admitted to the CICU. Methods: We conducted a retrospective cohort study of adult patients admitted to the Mayo Clinic CICU (2007-2018) with confirmed acute IE, identified via database query and manual chart review. Patients were further categorized by cardiac surgery status: performed, indicated but declined, or not indicated. Primary outcomes were all-cause mortality at 30-days and 1-year, analyzed using Kaplan-Meier and Cox proportional-hazard analysis. Models were adjusted for known predictors. Results: Overall, 233 CICU patients met criteria for IE. Median age was 64.0 years; 49 were female. In total, 104 patients had native valve IE; 128 had prosthetic or implantable device-associated IE. Staphylococcus aureus was the most prevalent organism (42.7%) and was present in 72.4% of 30-day deaths. Cardiac surgery was indicated in 182 (78.1%) patients - 129 patients underwent surgery, while 53 declined; 48 patients did not have indications. By 30 days, 58 (24.9%) patients died; significant predictors included older age, higher illness severity scores, and greater need for critical care therapies. The 30-day mortality estimates were markedly higher for patients who declined surgery (60.4%, adj. HR 4.17, 95% CI 2.02-8.52, p <0.001), and lower for those who received surgery vs those without surgical indications (11.9% vs 23.8%, adj. HR 0.44, 95% CI 0.20-0.98, p=0.04) (Figure 1). By 1-year, 93 (39.9%) patients died, including 36 (20.5%) hospital survivors. The 1-year mortality estimates were markedly higher for patients who declined surgery (85.1%, adj. HR 5.46, 95% CI 2.87-10.39, p <0.001), but was similar for patients who received surgery to those without surgical indications (31.8% vs 29.3%, adj. HR 0.94, 95% CI 0.49-1.78, p=0.84) (Figure 2). Conclusion: IE requiring CICU admission carries substantial mortality despite acute management. Higher severity scores, comorbidities, and intensive care interventions predict mortality. Early cardiac surgery improved short-term outcomes, but long-term mortality remains high.
Ischemic monomelic neuropathy as a consequence of intraoperative in-sheath thrombosis
Patel, Parth , Battenberg, Ashley, Wetmore, Emma, Devalapalli, Aditya P., Patel, Parth S , Jin, Mauricio F. , Devalapalli, Aditya, Wetmore, Emma

Mayo Clinic

The Journal of Vascular Access | August 1, 2025 | Volume: 27 | Issue: 2 | Pages: 838-841

10.1177/11297298251360931 | PMID 40745934 Get It

Ischemic monomelic neuropathy (IMN) is a rare peripheral neuropathy caused by limb ischemia and subsequent nerve degeneration, typically manifesting with unilateral pain, paresthesia, and numbness without overt signs of limb ischemia. This case report describes a 59-year-old female with extensive peripheral artery disease who developed IMN in her right lower extremity following an acute, intraoperative in-sheath thrombosis during a right femoral endarterectomy and external iliac artery stent placement, a rare etiology distinct from the more commonly reported associations with bypass surgery or hemodialysis access. Despite successful intraoperative revascularization, the patient developed diminished motor and sensory function with unremitting pain, and subsequent electromyography confirmed a length-dependent neuropathy with features of denervation, consistent with IMN. This case underscores the critical need for clinicians to consider IMN in the differential diagnosis of post-procedural neuropathic pain, even in the absence of classic ischemic signs and following seemingly successful vascular interventions, as acute thrombotic events during vascular procedures can precipitate this debilitating condition.
Twist of Fate: Life-Threatening SMA Thrombosis Caused by Mesenteric Torsion Post-Roux-en-Y Weight Loss
Ebrahim, Mohamed A. , Isha, Shahin , Bedross, Andranik, Patel, Parth M. , Kumar, Ashok , Ebrahim, Mohamed Ayman , Shahin, Isha

Mayo Clinic

Oxford Medical Case Reports | May 28, 2025 | Volume: 2025 | Issue: 5 | Pages: No page available

10.1093/omcr/omaf025 | PMID 40443859 Get It

Abstract Superior mesenteric artery (SMA) thrombosis is rare yet critical illness that can result in lethal bowel ischemia and infarction. This report details a case of SMA thrombosis with associated superior mesenteric vein (SMV) narrowing, secondary to mesenteric torsion in a 26-year-old female with history of Roux-en-Y gastric bypass surgery. The patient’s presenting symptoms were severe epigastric pain, vomiting, and significant anemia. Imaging confirmed SMA thrombosis with early signs of bowel ischemia. Interventional radiology promptly performed an SMA angiogram and initiated thrombolysis with a tenecteplase infusion, which led to near-complete resolution of the thrombus. This case draws attention to the necessity for early diagnosis and swift management of SMA thrombosis, particularly in post-surgical patients with altered gastrointestinal anatomy. The resolution of this case demonstrates the value of a collaborative care, combining interventional radiology and general surgery to prevent bowel ischemia.
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC–Alarmin Axis
Vincelette, Nicole D. , Yu, Xiaoqing , Moon, Jungwon , Su, Siyuan , Cheng, Chia‐Ho, Sammut, Rinzine , Razabdouski, Tiffany N. , Nguyen, Hai V. , Eksioglu, Erika A. , Ali, Najla Al , Patel, Parth , Lee, Dae Hyun , Nakanishi, Shima , Hyjek, Elizabeth , Murphy, Daniel J. , Lee, Daesung , Kuykendall, Andrew , Moon, Jungwon , Su, Siyuan , Cheng, Chia-Ho , Sammut, Rinzine , Razabdouski, Tiffany N , Nguyen, Hai V , Eksioglu, Erika A , Chan, Onyee , Al Ali, Najla , Patel, Parth C , Lee, Dae H , Nakanishi, Shima , Ferreira, Renan B , Hyjek, Elizabeth , Mo, Qianxing , Cory, Suzanne , Lawrence, Harshani R , Zhang, Ling , Murphy, Daniel J , Komrokji, Rami S , Lee, Daesung , Kaufmann, Scott H , Cleveland, John L , Yun, Seongseok , Chan, Onyee , Zhang, Ling , Komrokji, Rami S. , Kaufmann, Scott H. , Cleveland, John L. , Yun, Seongseok

Mayo Clinic

Blood Cancer Discovery | May 7, 2024 | Volume: 5 | Issue: 4 | Pages: 276-297

10.1158/2643-3230.bcd-23-0210 | PMID 38713018 Get It

Abstract Despite advances in understanding the genetic abnormalities in myeloproliferative neoplasms (MPN) and the development of JAK2 inhibitors, there is an urgent need to devise new treatment strategies, particularly for patients with triple-negative (TN) myelofibrosis (MF) who lack mutations in the JAK2 kinase pathway and have very poor clinical outcomes. Here we report that MYC copy number gain and increased MYC expression frequently occur in TN-MF and that MYC-directed activation of S100A9, an alarmin protein that plays pivotal roles in inflammation and innate immunity, is necessary and sufficient to drive development and progression of MF. Notably, the MYC-S100A9 circuit provokes a complex network of inflammatory signaling that involves numerous hematopoietic cell types in the bone marrow microenvironment. Accordingly, genetic ablation of S100A9 or treatment with small molecules targeting the MYC-S100A9 pathway effectively ameliorates MF phenotypes, highlighting the MYC–alarmin axis as a novel therapeutic vulnerability for this subgroup of MPNs. Significance: This study establishes that MYC expression is increased in TN-MPNs via trisomy 8, that a MYC-S100A9 circuit manifest in these cases is sufficient to provoke myelofibrosis and inflammation in diverse hematopoietic cell types in the BM niche, and that the MYC-S100A9 circuit is targetable in TN-MPNs.
MYC-Alarmin Axis As a Novel Oncogenic Driver in a Subgroup of Triple Negative Myeloproliferative Neoplasms
Yu, Xiaoqing , Moon, Jungwon , Su, Siyuan , Cheng, Chia‐Ho, Sammut, Rinzine , Ali, Najla H. Al, Patel, Parth , Nakanishi, Shima , Lee, Daesung , Su, Siyuan , Patel, Parth C , Vincelette, Nicole D. , Kuykendall, Andrew , Nguyen, Hai V. , Eksioglu, Erika A. , Chan, Onyee , Lee, Dae Hyun , Ferreira, Renan B , Mo, Qianxing , Cory, Suzanne , Lawrence, Harshani R , Zhang, Ling , Murphy, Daniel J. , Komrokji, Rami S. , Kaufmann, Scott H. , Cleveland, John L. , Yun, Seongseok

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 994-994

10.1182/blood-2023-174383 Get It

Primary Myelofibrosis (PMF) is an aggressive myeloproliferative neoplasm (MPN) characterized by constitutional symptoms, cytopenias, splenomegaly, extramedullary hematopoiesis, bone marrow (BM) fibrosis, and a propensity to transform to acute myeloid leukemia (AML). Despite advances in understanding the underlying genetic abnormalities in MPN and the development of JAK2 inhibitors to treat MF, there is an urgent need to devise new treatment strategies, particularly for triple negative myelofibrosis (TN-MF) cases that lack mutations in the JAK2 kinase pathway and who have inferior outcomes. To identify potential oncogenic drivers in TN-MF, we performed cytogenetic analyses and targeted exome sequencing of 98 genes commonly mutated in myeloid malignancies in 584 MF patients identified from the Total Cancer Care database at Moffitt Cancer Center. Notably, there were no significant differences in the somatic mutation profiles (other than JAK2 activating mutations) between TN vs. JAK2/CALR/MPL mutant MF patients. However, trisomy of chromosome 8 occurs more frequently in TN-MF vs. other subtypes (26.7% vs. 6.2%, p=0.0001). To identify oncogenic drivers in trisomy 8+ TN-MF, we performed scRNA-seq analysis from 18,651 cells ( n=15,850 from 3 normal donors and n=2,801 from a trisomy 8+ TN-MF patient) and identified a total of 1,260 genes that are differentially regulated in hematopoietic stem cells (HSCs) of trisomy 8+ TN-MF compared to normal donors. Among these, 131 genes were located on chromosome 8 and MYC was one of the top 5 genes that are significantly upregulated in trisomy 8+ HSCs. Additional immunohistochemistry staining demonstrated that MYC protein levels in BM cells were significantly higher in trisomy 8+ TN-MF patients vs. trisomy 8- patients. To assess whether MYC might be a driver of MPN, we established an Mx1-Cre +/-;Rosa26 LSL-MYC/LSL-MYC transgenic mouse model that inducibly overexpresses MYC in HSCs following treatment of polyinosinic-polycytidylic acid (pIpC). Forced MYC expression induced profound anemia, monocytosis, megakaryocytic atypia, splenomegaly, increased BM collagen deposition/fibrosis, extramedullary hematopoiesis in spleen and liver, and significantly reduced OS vs. Mx1-Cre +/- wild type controls (median OS 258 days vs. not reached (NR), p&lt;0.0001). MYC also promoted expansion of HSCs, myeloid progenitors, and Gr-1 +/CD11b + mature myeloid cells in BM and spleen; thus, MYC was sufficient to provoke MF-like disease independent of JAK2 pathway mutations. Subsequent scRNA-seq analysis of 25,232 cells ( n=13,552 from control and n=11,680 from a MYC transgenic mouse) revealed that S100a9 mRNA levels were increased by MYC in most major hematopoietic cell types. Supporting oncogenic roles of S100A9 in MYC-driven MF, deletion of S100a9 in Mx1-Cre +/-;Rosa26 LSL-MYC/LSL-MYC;S100a9 -/- mice abolished MYC-induced MF phenotypes and significantly improved OS (median OS NR vs. 225 days, p=0.0345). To test whether inhibition of MYC can suppress MF disease progression in vivo, lethally irradiated CD45.1 +/CD45.2 + WT mice were transplanted with BM cells harvested from CD45.2 + Mx1-Cre +/-;Rosa26 LSL-MYC/LSL-MYC mice that were treated with pIpC 20 weeks prior to transplant. MYCi975, a small molecule that inhibits MYC, reduced MYC and S100a9 protein levels in BM and spleen cells. Further, MYCi975 effectively suppressed MYC-driven MF phenotypes and disease progression, and significantly improved OS (median OS NR vs. 252 days, p=0.0109). In summary, our studies are the first to describe an oncogenic role of MYC in MF pathogenesis, where MYC provokes an alarmin-driven inflammatory circuit, and where the MYC-S100A9 axis represents a therapeutic vulnerability for TN-MF patients. Accordingly, our results provide a strong rationale for testing agents targeting MYC or S100A9 in early phase clinical trials in MPNs having increased MYC levels or activity.
S806 Safety and Efficacy of Continuous vs Intermittent Terlipressin for Acute Esophageal Variceal Bleeding - A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Nivedita, Fnu, Loganathan, Priyadarshini , Moond, Vishali , Kassab, Lena L., Patel, Parth , Simadibrata, Daniel Martin , Mohan, Babu P.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S593-S594

10.14309/01.ajg.0000952864.11206.9b Get It

Esophageal Lichen Planus
Aby, Elizabeth S. , Eckmann, Jason D. , Katzka, David A. , Beveridge, Claire , Triggs, Joseph , Abdi, Tsion, Turner, Kevin , Antunes, Catiele , Zhuo, Justin , Kamal, A. N. , Gyawali, C. Prakash , Sloan, Joshua A. , Abimansour, Jad, Sloan, Joshua A , Gyawali, C P , AbiMansour, Jad P. , Dbouk, Mohamad H. , Kamal, Afrin N., Patel, Parth

Mayo Clinic

Journal of Clinical Gastroenterology | July 12, 2023 | Volume: 58 | Issue: 5 | Pages: 427-431

10.1097/mcg.0000000000001885 | PMID 37436831 Get It

Goals: To better understand the characteristics, treatment approaches, and outcomes of patients with esophageal lichen planus (ELP). Background: ELP is a rare, often unrecognized and misdiagnosed disorder. Data on this unique patient population are currently limited to small, single-center series. Study: A multicenter, retrospective descriptive study was conducted of adults diagnosed with ELP over a 5-year period, between January 1, 2015, and October 10, 2020, from 7 centers across the United States. Results: Seventy-eight patients (average age 65 y, 86% female, 90% Caucasian) were included. Over half had at least 1 extraesophageal manifestation. Esophageal strictures (54%) and abnormal mucosa (50%) were frequent endoscopic findings, with the proximal esophagus the most common site of stricture. Approximately 20% had normal endoscopic findings. Topical steroids (64%) and/or proton pump inhibitors (74%) dominated management; endoscopic response favored steroids (43% vs. 29% respectively). Almost half of the patients required switching treatment modalities during the study period. Adjunctive therapies varied significantly between centers. Conclusions: Given its at times subtle clinical and endoscopic signs, a high index of suspicion and biopsy will improve ELP diagnosis, especially in those with extraesophageal manifestations. Effective therapies are lacking and vary significantly. Prospective investigations into optimal treatment regimens are necessary.